跳至主要内容
临床试验/NCT01809405
NCT01809405Unknown不适用

Validation of Sexual Function Scale in Female Cancer

National Cancer Center, Korea1 个研究点 分布在 1 个国家目标入组 1,130 人开始时间: 2012年12月最近更新:
适应症

试验速览

阶段
不适用
入组人数
1,130
试验地点
1
主要终点
sexuality

研究概览

简要总结

To validate the FSFI(Female Sexual Function Index)-K, FSFI - 6 item and Quality of Sexual Function(QSF) version in Korean language of the cancer patients.

详细描述

Due to the observational nature of the study which aims to evaluate the internal consistency and validity of the Korean version of Questionnaire, formal sample size and power calculations were not performed. When the number of observations (items) per subject ranges from 4 to 6, roughly 152-199 patients are required to show 10% increase in intraclass correlation from baseline ICC of 30% with 85% power and 5% type I error rate. The sample size was determined based on this calculation and practical considerations.

The pilot study will be performed based on 30 people (include reference), and the main study will include 1100 people (considering 10% drop-out from 200 people in each group) cancer type (ovary, cervix, endometrium, and breast) and healthy female. Total 1130 patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Healthy women
  • Female without history of cancer
  • Cancer free as of the most recent linkage
  • At least 18 years of age
  • Able to speak and read Korean
  • Sexual activity within 3months.
  • Female cancer patient
  • History of gynecological or breast cancer
  • At least 18 years of age
  • Able to speak and read Korean
  • Sexual activity within 3months.

排除标准

  • Women who are unable to complete the questionnaires.
  • Refuse to participate in the survey.

结局指标

主要结局

sexuality

时间窗: 2-4 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Sang-Yoon Park

Senior researcher

National Cancer Center, Korea

研究点 (1)

Loading locations...

相似试验

Validation of Sexual Function Scale in Female Cancer | 临床试验